When the next patient asks me about a game-changing HIV prevention tool, I hope I can say, “It’s already here and available to everyone who needs it.” ...
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
Biotech giant Gilead Sciences, Inc. GILD has put up a strong ... Gilead has a market-leading portfolio of HIV treatments. The company’s consistent efforts to develop additional innovative ...
HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter. HB-500 ...
Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...
The the stock of HIV and hepatitis C drugmaker has fallen ... alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback